SynthesisEuropean journal of clinical pharmacology2023
Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting.Open forum infectious diseases · 2026Trial
- Pharmacist-driven antimicrobial stewardship: evolving roles in clinical practice.Journal of pharmaceutical health care and sciences · 2026Review
- Targeting Tumour Microtubes to Disrupt Glioma Networks.Research square · 2026Article
- Successful Management of Infective Endocarditis Utilizing Rapid High-performance Liquid Chromatography-based Therapeutic Drug Monitoring: Balancing Linezolid Efficacy and Thrombocytopenia Risk.Internal medicine (Tokyo, Japan) · 2026Article
- Incidence and sex-related risk factors of linezolid-associated adverse drug reactions identified through electronic health records.Translational and clinical pharmacology · 2026Article
- Addition of lactoferrin increases efficacy of three Kayviruses and limits the inflammatory response in pulmonary epithelial cells.Applied microbiology and biotechnology · 2026Article
- Beyond 'One Size Fits All': Abatement of Linezolid-Induced Thrombocytopenia Through Therapeutic Drug Monitoring and Precision Dosing-A Case Study.Case reports in infectious diseases · 2026Article
- Prediction model of thrombocytopenia on patients using linezolid: a ranked-based covariate selection with multi-center data.Frontiers in pharmacology · 2026Article
- Linezolid Related Adverse Effects in Different Populations: A Review.Current drug safety · 2026Review
- Effect of traumatic brain injury on the trough concentration of linezolid in patients with hospital-acquired pneumonia.Scientific reports · 2025Article
- High accumulation of linezolid and its major metabolite in the serum of patients with hepatic and renal dysfunction is significantly associated with thrombocytopenia and anemia.Microbiology spectrum · 2025Article
- The Effect of Antibiotics on the Nervous System: Importance for Anesthesiology and Intensive Care.Antibiotics (Basel, Switzerland) · 2025Review
- Evaluating anti-MRSA antibiotic stewardship with a focus on trends in consumption and resistance in a tertiary hospital in Alexandria, Egypt from 2019 to 2023.Archives of public health = Archives belges de sante publique · 2025Article
- Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study.International journal of clinical pharmacy · 2025Observational
- Evaluation of the consumption pattern and efficacy of Linezolid in COVID-19 hospitalized patients in a hospital in Tehran-Iran.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Review
- Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.Frontiers in pharmacology · 2025Article
- Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment.Drug design, development and therapy · 2025Article
- Thinking Three-Dimensionally: A Self- and Externally-Controlled Approach to Screening for Drug-Drug-Drug Interactions Among High-Risk Populations.Clinical pharmacology and therapeutics · 2024Article
- Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study.Therapeutic advances in drug safety · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe incidence of linezolid-induced thrombocytopenia (LIT) has been reported to vary widely across studies. We performed a meta-analysis to identify the risk factors for thrombocytopenia among patients who received linezolid treatment.
methodsThe PubMed, Embase and Cochrane Library databases were searched from inception to November 2022 to identify eligible studies. Data on the potential predictors of incidence in LIT were pooled using a random effects model. Sensitivity analyses were performed to determine the robustness of the results when significant heterogeneity was observed.
resultsForty observational studies involving 6454 patients treated with linezolid were included in the analysis. LIT was estimated to occur in 37% of patients. The following important factors were associated with the incidence of LIT: advanced age, body mass index, concurrent renal impairment or liver disease, abnormal laboratory parameters (including white blood cell count, serum creatinine, baseline platelet count, albumin, creatinine clearance rate, and estimated glomerular filtration rate), treatment duration and renal replacement therapy.
conclusionsA variety of risk factors related to the occurrence of LIT were revealed in our analysis. Early identification of these factors could help patients improve clinical outcomes.
Indexed as
Identifiers
37578552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.